Self-reported fatigue common among optimally treated HIV patients: No correlation with cerebral FDG-PET scanning abnormalities

NeuroImmunoModulation

Volumn 13, Issue 2, 2006, Pages 69-75

  Andersen, Åse B ^a,b   Law, Ian ^a   Ostrowski, Sisse R ^a   Lebech, Anne Mette ^a   Høyer Hansen, Gunilla ^a   Højgaard, Liselotte ^a   Gerstoft, Jan ^a   Ullum, Henrik ^a   Kjær, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Anti retroviral treatment; Cytokine profile; Fatigue; Fluorine 18 fluorodeoxyglucose positron emission tomography brain scanning; Interleukin 6; Soluble urokinase receptor; Tumour necrosis factor

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYTOKINE; DIDANOSINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INTERLEUKIN 6; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; UROKINASE RECEPTOR; ZALCITABINE;

ADULT; ANAMNESIS; APPARATUS; ARTICLE; BRAIN METABOLISM; CD4 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENMARK; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FATIGUE; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGE ANALYSIS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SELF REPORT;

ADULT; AGED; AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CEREBRAL CORTEX; COHORT STUDIES; COMORBIDITY; FATIGUE SYNDROME, CHRONIC; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; QUESTIONNAIRES; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751311532     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095222     Document Type: Article

References (34)

1. Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S: Fatigue in ambulatory AIDS patients. J Pain Symptom Manage 1998;15:159-167.
2. Tucker KA, Robertson KR, Lin W, et al: Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004;157:153-162.
3. Decrion AZ, Dichamp I, Varin A, Herbein G: HIV and inflammation. Curr HIV Res 2005;3:243-259.
4. Bruunsgaard H: Effects of tumor necrosis factor-α and interleukin-6 in elderly populations. Eur Cytokine Netw 2002;13:389-391.
5. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K: Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 2003;61:255-260.
6. Perry RT, Collins JS, Wiener H, Acton R, Go RC: The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 2001;22:873-883.
7. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H: Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:337-342.
8. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H: High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:23-31.
9. Sidenius N, Nebuloni M, Sala S, et al: Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol 2004;157:133-139.
10. Thompson PM, Dutton RA, Hayashi KM, et al: Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4(+) T lymphocyte decline. Proc Natl Acad Sci USA 2005;102:15647-15652.
11. Heyes MP, Ellis RJ, Ryan L, et al: Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain 2001;124:1033-1042.
12. Quan N, Herkenham M: Connecting cytokines and brain: a review of current issues. Histol Histopathol 2002;17:273-288.
13. Herholz K, Salmon E, Perani D, et al: Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-316.
14. Silverman DHS, Gambhir SS, Huang HWC, et al: Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002;43:253-266.
15. Rottenberg DA, Moeller JR, Strother SC, et al: The metabolic pathology of the AIDS dementia complex. Ann Neurol 1987;22:700-706.
16. Rottenberg DA, Sidtis JJ, Strother SC, et al: Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996;37:1133-1141.
17. Chene G, Angelini E, Cotte L, et al: Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34:649-657.
18. Mendoza TR, Wang XS, Cleeland CS, et al: The rapid assessment of fatigue severity in cancer patients - use of the Brief Fatigue Inventory. Cancer 1999;85:1186-1196.
19. Riisbro R, Piironen T, Brunner N, et al: Measurement of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay 2002;25:53-56.
20. Riisbro R, Christensen IJ, Piironen T, et al: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002;8:1132-1141.
21. Raichle ME: Circulatory and metabolic correlates of brain function in normal humans; in Plum F (ed): Handbook of Physiology: The Nervous System. Baltimore, Williams & Wilkins, 1987, pp 643-674.
22. Mosconi L: Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510.
23. Silverman DH: Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594-607.
24. Lewellen TK, Kohlmyer SG, Miyaoka RS, Kaplan MS: Investigation of the performance of the general electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci 1996;43:2199-2206.
25. Drzezga A, Lautenschlager N, Siebner H, et al: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-1113.
26. Ishii K, Mori T, Hirono N, Mori E: Glucose metabolic dysfunction in subjects with a clinical dementia rating of 0.5. J Neurol Sci 2003;215:71-74.
27. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
28. Brew BJ: Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. Aids 2004;18:S75-S78.
29. Cysique LAJ, Maruff P, Brew BJ: Antiretroviral therapy in HIV infection - are neurologically active drugs important? Arch Neurol 2004;61:1699-1704.
30. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA: HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Diff 2005;12:878-892.
31. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK: Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004;78:10133-10148.
32. Koivumaa-Honkanen H, Honkanen R, Viinamaki H, Heikkila K, Kaprio J, Koskenvuo M: Self-reported life satisfaction and 20-year mortality in healthy Finnish adults. Am J Epidemiol 2000;152:983-991.
33. Henderson M, Safa F, Easterbrook P, Hotopf M: Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med 2005;6:347-352.
34. Ofotokun I: Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. Top HIV Med 2005;13:79-83.